Dr. Li is a member of the American Chemical Society, and has earned a doctoral degree in medicinal chemistry from the Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences in Guangzhou, China. He collaborates with UTEP faculty members in the realms of drug discovery and development, as well as biomarker studies utilizing high-resolution mass spectrometry. Notably, he has taken the lead in a project involving the growth of tobacco using 13CO2 labeling, a venture that has encompassed the plants' lifecycle from seed germination to flowering since 2019.

• Ph D in Medicinal Chemistry, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences (2014)
• BS in Traditional Chinese Medicine, Tongji Medical School, Huazhong University of Science and Technology (2009)

• Design, Synthesis, and Biological Evaluation of Potent and Selective PROTAC Degraders of Oncogenic KRAS(G12D). Journal of medicinal chemistry (2024), C Zhou, Z Fan, Y Gu, Z Ge, Z Tao, R Cui, Y Li , G Zhou, R Huo, M Gao, D Wang, W He, M Zheng, S Zhang, Tao Xu.
• Mass Spectrometry-Based Metabolic Profiling of Urinary Metabolites of <i>N</i>′-Nitrosonornicotine (NNN) in the Rat Chemical Research in Toxicology 36 5 (2023), Yupeng Li, Romel P. Dator, Laura A. Maertens, Silvia Balbo, Stephen S. Hecht.
• Discovery of a Potent, Cooperative, and Selective SOS1 PROTAC ZZ151 with In Vivo Antitumor Efficacy in KRAS-Mutant Cancers Journal of Medicinal Chemistry 66 6 (2023), Zehui Zhou, Guizhen Zhou, Chuan Zhou, Zisheng Fan, Rongrong Cui, Yupeng Li, Rui Li, Yuejiao Gu, Huajie Li, Zhiming Ge, Xiaojia Cai, Bing Jiang, Dan Wang, Mingyue Zheng, Tianfeng Xu, Sulin Zhang.
• Ionizable drug delivery systems for efficient and selective gene therapy. Military Medical Research 10 1 (2023), Y Q. Zhang, R R. Guo, Y H. Chen, T C. Li , W Z. Du , R W. Xiang, J B. Guan, Y P. Li , Y Y. Huang, Z Q. Yu, Y Cai, P Zhang, G X. Ling.
• Design, Synthesis, and Bioevaluation of Pyrido[2,3-<i>d</i>]pyrimidin-7-ones as Potent SOS1 Inhibitors ACS Medicinal Chemistry Letters 14 2 (2023), Meiying Liu, Guizhen Zhou, Wenhong Su, Yuejiao Gu, Mingshan Gao, Kun Wang, Ruifeng Huo, Yupeng Li, Zehui Zhou, Kaixian Chen, Mingyue Zheng, Sulin Zhang, Tianfeng Xu.
• Characterization and quantitation of busulfan DNA adducts in the blood of patients receiving busulfan therapy. Molecular therapy oncolytics 28 (2023), V Guidolin, Y Li , F C. Jacobs, M L. MacMillan, P W. Villalta, S S. Hecht, S Balbo.
• Mass Spectrometric Quantitation of <i>N</i>′-Nitrosonornicotine-1<i>N</i>-oxide in the Urine of Cigarette Smokers and Smokeless Tobacco Users Chemical Research in Toxicology 35 9 (2022), Yupeng Li, Stephen S. Hecht.
• Carcinogenic components of tobacco and tobacco smoke: A 2022 update Food and Chemical Toxicology 165 (2022), Yupeng Li, Stephen S. Hecht.
• Recent Developments in the Synthesis of Indole‐Pyrazole Hybrids ChemistrySelect 7 21 (2022), K. Fabitha, Munugala Chandrakanth, Rakendu N. Pramod, C. G. Arya, Yupeng Li, Janardhan Banothu.
• Metabolism and DNA Adduct Formation of Tobacco-Specific N-Nitrosamines International Journal of Molecular Sciences 23 9 (2022), Yupeng Li, Stephen S. Hecht.
• Metabolic Activation and DNA Interactions of Carcinogenic N-Nitrosamines to Which Humans Are Commonly Exposed International Journal of Molecular Sciences 23 9 (2022), Yupeng Li, Stephen S. Hecht.
• Discovery of the First-in-Class Agonist-Based SOS1 PROTACs Effective in Human Cancer Cells Harboring Various KRAS Mutations Journal of Medicinal Chemistry 65 5 (2022), Chuan Zhou, Zisheng Fan, Zehui Zhou, Yupeng Li, Rongrong Cui, Chaoyi Liu, Guizhen Zhou, Xingxing Diao, Hualiang Jiang, Mingyue Zheng, Sulin Zhang, Tianfeng Xu.
• Design, Synthesis, and Biological Evaluation of Novel EGFR PROTACs Targeting Del19/T790M/C797S Mutation ACS Medicinal Chemistry Letters 13 2 (2022), Hualin Zhang, Ruliang Xie, Hawaa AI-furas, Yupeng Li, Qingxia Wu, Jian Li, Fang Xu, Tianfeng Xu.
• Coumarin–benzimidazole hybrids: A review of developments in medicinal chemistry European Journal of Medicinal Chemistry 227 (2022), Arya C. G, Ramesh Gondru, Yupeng Li, Janardhan Banothu.
• Identification of an <i>N′</i>-Nitrosonornicotine-Specific Deoxyadenosine Adduct in Rat Liver and Lung DNA Chemical Research in Toxicology 34 4 (2021), Yupeng Li, Stephen S. Hecht.
• Investigation of 2′-Deoxyadenosine-Derived Adducts Specifically Formed in Rat Liver and Lung DNA by <i>N</i>′-Nitrosonornicotine Metabolism Chemical Research in Toxicology 34 4 (2021), Yupeng Li, Erik S. Carlson, Adam T. Zarth, Pramod Upadhyaya, Stephen S. Hecht.
• Design and Optimization of 3′-(Imidazo[1,2-<i>a</i>]pyrazin-3-yl)-[1,1′-biphenyl]-3-carboxamides as Selective DDR1 Inhibitors ACS Medicinal Chemistry Letters 11 3 (2020), Cheng Mo, Zhang Zhang, Yupeng Li, Minhao Huang, Jian Zou, Jinfeng Luo, Zheng-Chao Tu, Yong Xu, Xiaomei Ren, Ke Ding, Xiaoyun Lu.
• Resolution and Quantitation of Mercapturic Acids Derived from Crotonaldehyde, Methacrolein, and Methyl Vinyl Ketone in the Urine of Smokers and Nonsmokers Chemical Research in Toxicology 33 2 (2020), Menglan Chen, Steven G. Carmella, Yupeng Li, Yingchun Zhao, Stephen S. Hecht.
• Mass Spectrometric Quantitation of Pyridyloxobutyl DNA Phosphate Adducts in Rats Chronically Treated with <i>N</i>′-Nitrosonornicotine Chemical Research in Toxicology 32 4 (2019), Yupeng Li, Bin Ma, Qing Cao, Silvia Balbo, Lijiao Zhao, Pramod Upadhyaya, Stephen S. Hecht.

No info available.

No info available.